What the impact of 44-week aflibercept data may mean in a real-world setting

David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.

Related Videos

View All

Related Content

Vial partners with RecensMedical in phase 3 clinical trial

January 27th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

January 26th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

January 26th 2023

Study: Atropine drops after glaucoma surgery may impair vision, prolong rehabilitation

January 26th 2023

Vial partners with RecensMedical in phase 3 clinical trial

January 27th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

January 26th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

January 26th 2023

Study: Atropine drops after glaucoma surgery may impair vision, prolong rehabilitation

January 26th 2023

Vial partners with RecensMedical in phase 3 clinical trial

January 27th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

January 26th 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

January 26th 2023

Study: Atropine drops after glaucoma surgery may impair vision, prolong rehabilitation

January 26th 2023

Related Content

---

Vial partners with RecensMedical in phase 3 clinical trial

Articles

---

Commercial real estate and your practice, part two with Colin Carr

Podcasts

---

Ocuphire Pharma’s ZETA-1 phase 2 trial of diabetic retinopathy candidate offers mixed results

Articles

---

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Podcasts

---

UT Southwestern ophthalmologist shares techniques for cataract surgery complications

Articles

---

Study: Atropine drops after glaucoma surgery may impair vision, prolong rehabilitation

Articles